| Identification | More | [Name]
Linarin | [CAS]
480-36-4 | [Synonyms]
ACACETIN-7-O-RUTINOSIDE
ACACETIN-7-RUTINOSIDE
BUDDLEOSIDE
BUDDLOSIDE
LINARIN
7-[[6-O-(6-deoxy-alpha-L-mannopyranosyl)-beta-D-glucopyranosyl]oxy]-5-hydroxy-4'-methoxyflavone
7-[[6-O-(6-deoxy-alpha-L-mannopyranosyl)-beta-D-glucopyranosyl]oxy]-5-hydroxy-2-(4-methoxyphenyl)-4H-benzopyran-4-one
Buddloside，Linarin
LINARIN WITH HPLC
ACACETIN-7-RUTINOSIDE hplc
7-((6-O-(6-Deoxy-alpha-L-mannopyranosyl)-beta-D-glucopyranosyl)oxy)-5-hydroxy-2-(4-methoxyphenyl)-4H-benzopyran-4-one
Acacetin-7-O-β-D-rutinoside
Buddleoflavonoloside
Linarigenin glycoside
Buddleoside，Linarin
7-[[6-O-(6-Deoxy-α-L-mannopyranosyl)-β-D-glucopyranosyl]oxy]-5-hydroxy-2-(4-methoxyphenyl)-4H-1-benzopyran-4-one
7-[[6-O-(6-Deoxy-α-L-mannopyranosyl)-β-D-glucopyranosyl]oxy]-5-hydroxy-4'-methoxyflavone | [EINECS(EC#)]
207-547-6 | [Molecular Formula]
C28H32O14 | [MDL Number]
MFCD00151178 | [Molecular Weight]
592.55 | [MOL File]
480-36-4.mol |
| Chemical Properties | Back Directory | [Melting point ]
258-260°C | [Boiling point ]
885.2±65.0 °C(Predicted) | [density ]
1.62±0.1 g/cm3(Predicted) | [storage temp. ]
Hygroscopic, -20°C Freezer, Under inert atmosphere | [solubility ]
Acetic Acid (Very Slightly, Heated), Acetonitrile (Slightly), DMSO (Slightly) | [form ]
Solid | [pka]
6.11±0.40(Predicted) | [color ]
White to Pale Beige | [Stability:]
Hygroscopic | [InChIKey]
YFVGIJBUXMQFOF-BWLJPJRBNA-N | [SMILES]
C12C(O)=CC(O[C@H]3[C@H](O)[C@H]([C@H](O)[C@@H](CO[C@@H]4O[C@H]([C@H](O)[C@@H](O)[C@H]4O)C)O3)O)=CC=1OC(C1C=CC(OC)=CC=1)=CC2=O |&1:6,7,9,10,12,15,17,18,20,22,r| | [CAS DataBase Reference]
480-36-4(CAS DataBase Reference) |
| Hazard Information | Back Directory | [Chemical Properties]
White crystalline powder, easily soluble in methanol, almost insoluble in ether, derived from wild chrysanthemum, great thistle, and small thistle. | [Uses]
Linarine (Diosmin EP Impurity E) is a naturally occurring flavone glycoside that was identified to possess potential sedative and anticonvulsant properties. | [in vivo]
Linarin (oral administration; 50-150 mg/kg; 8 weeks) can improve bone loss in ovariectomized mice[2]. | Animal Model: | Ovariectomy treated female C57/BL6 mice[2] | | Dosage: | 50 and 150 mg/kg | | Administration: | Oral administration (p.o.); 8 weeks | | Result: | Dose?dependently preserved the trabecular bone microarchitecture of ovariectomized mice.
Slightly increased BMD compared to the control OVX group.
Significantly decreased OVX-induced serum ALP and OCN levels. |
| [IC 50]
AChE |
|
|